Treatment reduces the risk of dementia by 17% in people with rheumatoid arthritis.
- DMARDs (disease modifying anti-rheumatic drugs) are a basic treatment.
- In France, the prevalence of rheumatoid arthritis is located at 0.4% of the population.
According to a new study, the incidence of dementia in people with rheumatoid arthritis is lower in patients receiving synthetic biological or targeted antirheumatic drugs (DMARDs) than in patients receiving conventional synthetic DMARDs. These results were presented at the annual meeting of the American College of Rheumatology.
A systemic disease
“Taking biologic or targeted synthetic antirheumatics reduced the risk of incidence of dementia by 17% compared to patients taking only conventional synthetic DMARDs,” said study author Sebastian Sattui, a rheumatology fellow.
“Rheumatoid arthritis is a systemic disease and can have cognitive implications. Our work again shows that treating rheumatoid arthritis can impact the overall health and quality of life of our patients,” he continues. 141,326 patients with rheumatoid arthritis were included in the study.
Joint destruction
Rheumatoid arthritis is a chronic inflammatory degenerative disease, progressing in flare-ups towards the deformation and destruction of the affected joints. In France, the prevalence of rheumatoid arthritis is located at 0.4% of the population.
DMARDs (disease modifying anti-rheumatic drugs) are a long-term treatment, which aims to control the clinical inflammatory manifestations of the disease, and to slow down its destructive evolution.
.
